CA2432428A1 — Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2002-06-27 · 24y expired
What this patent protects
The present invention relates to quinazoline derivatives of general formula (see formula I) wherein R a, R b and R c are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or orga…
USPTO Abstract
The present invention relates to quinazoline derivatives of general formula (see formula I) wherein R a, R b and R c are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.